Terremoto Biosciences will receive $ 75 million to develop covalent drugs BioSpace
Terremoto Biosciences is headquartered in San Francisco launched with $ 75 million in A-line funding for the development of highly targeted small molecule drugs. Funding was co-managed OrbiMed and Third Rock Ventures. With funding, Terremoto plans to expand its lysine-focused covalence platform and create therapies for previously incurable diseases. “Terremoto redefines what was once considered …
Terremoto Biosciences will receive $ 75 million to develop covalent drugs BioSpace Read More »